Jun 28 |
FSD Pharma, Inc. Wins Final Judgment to Confirm Arbitration Award of $3,059,998 Plus Interest Entered Against Dr. Raza Bokhari, Currently Serving as Chairman and CEO of Medicus Pharma Ltd.
|
Jun 27 |
FSD Pharma Receives Ethics Committee Approval for a Phase-1 Multiple Ascending Doses Clinical Trial for Lucid-21-302 (Lucid-MS) in Australia
|
Jun 4 |
FSD Pharma Receives Institutional Review Board Approval to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol Intoxication
|
May 28 |
FSD Pharma Submits a Clinical Trial Protocol to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol Intoxication
|
May 24 |
FSD Pharma Provides Corporate Update
|
May 16 |
FSD Pharma Provides Update on Celly Nu's New Packaging for unbuzzd(TM)
|
May 7 |
FSD Pharma Submits a Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in Australia
|
Apr 30 |
FSD Pharma Signs Agreement with Applied Science and Performance Institute (ASPI) to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of unbuzzd(TM) in an Induced State of Alcohol Intoxication
|
Apr 22 |
FSD Pharma Provides Another Update on Celly Nu's Anticipated Launch of unbuzzd(TM)
|
Apr 17 |
FSD Pharma expands pipeline investigation to include weight loss and liver health products
|